Clevidipine: Nursing Drug Guide, IV Titration & Hypotension
Rapid IV titration can overshoot blood pressure goals and cause hypotension with reflex tachycardia; prolonged lipid emulsion infusions need volume limits, and stopping without oral transition risks rebound hypertension hours later.
Clevidipine (Cleviprex) lowers blood pressure within minutes. Upward titration without reassessment can cause symptomatic hypotension and compensatory tachycardia that worsens myocardial oxygen demand. The ultrashort offset means blood pressure may rebound if oral antihypertensive therapy is not in place when the infusion stops—monitor for at least 8 hours after prolonged infusions without transition.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Clevidipine safety is titration discipline: screen soy and egg allergy, run only through a dedicated line, track cumulative lipid volume, and plan oral antihypertensive transition before stopping the infusion.
Most common brand names
Clevidipine is marketed as Cleviprex (clevidipine injectable emulsion, 0.5 mg/mL). Verify the MAR lists both generic and brand names—pump programming errors often trace to concentration assumptions.
Do not confuse Cleviprex vials with other IV vasodilator bags or syringes in the medication room; lipid emulsion appearance differs from clear solutions.
Why we give it — Indications
Per Cleviprex prescribing information, clevidipine is indicated to reduce blood pressure when oral therapy is not feasible or not desirable—common in perioperative, neurocritical, and ICU settings where rapid, titratable control is needed.
| Use | Detail |
|---|---|
| Acute blood pressure reduction | IV therapy when oral antihypertensives cannot be used or are inappropriate for the clinical situation |
| Perioperative / procedural hypertension | Short-interval titration to prescriber-defined blood pressure targets after surgery or during hypertensive urgency when rapid control is required |
| Transition planning | Bridge only—coordinate oral agents before discontinuation to avoid rebound, especially in patients with angina or prior hypertensive crises |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Clevidipine is a dihydropyridine calcium channel blocker that selectively dilates arterioles, reducing systemic vascular resistance and blood pressure. Onset is rapid (about 2–4 minutes) and offset is fast (about 5–15 minutes) because the drug is metabolized by blood and tissue esterases—not hepatic or renal pathways. Like other dihydropyridines such as amlodipine, clevidipine can increase heart rate reflexively when blood pressure falls abruptly.
The injectable emulsion delivers drug in a lipid vehicle (0.2 g/mL lipid)—nurses must account for lipid load when patients also receive parenteral nutrition or other lipid-containing infusions.
Dosing overview
Individualize titration to the ordered blood pressure range. Double-check pump rate in mg/hour against the 0.5 mg/mL concentration before every rate change.
24-hour lipid and rate limits (labeling)
| Parameter | Limit | Nursing note |
|---|---|---|
| Maximum infusion rate | Most patients ≤16 mg/hour | Reassess if orders approach this ceiling—overshoot hypotension risk rises |
| 24-hour volume cap | 1000 mL total infusion volume | At max rate and concentration, approximates ~21 mg/hour average—track mL infused on handoff |
| Lipid content | 0.2 g/mL in emulsion | Add lipid load from TPN and other emulsions when planning prolonged therapy |
On a small screen, swipe or scroll sideways to see the full table.
Renal / hepatic impairment: No dose adjustment specified—metabolism is extrahepatic via esterases. Still monitor perfusion and blood pressure trends in organ dysfunction.
Missed dose: Not applicable to continuous infusion—if infusion was interrupted, verify line patency, vial beyond 12-hour puncture limit, and prescriber direction before restarting.
Before you give it — Safety check
Pretreatment checks
- Perform medication reconciliation—document oral antihypertensives held or continued and plan transition before clevidipine stop
- Screen allergy to soy, egg, or lipid emulsion components; confirm no defective lipid metabolism disorder
- Assess for aortic valve stenosis—severe disease is contraindicated
- Establish blood pressure targets, telemetry availability, and urine output baseline
- Calculate cumulative infusion volume and lipid load if therapy may exceed several hours
Contraindications
- Allergy to soybeans, soy products, eggs, or egg products
- Defective lipid metabolism (e.g., pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)
- Severe aortic stenosis
Warnings (labeling)
- Hypotension and reflex tachycardia: Decrease infusion rate when blood pressure falls excessively or heart rate rises compensatorily
- Negative inotropy: Use caution in heart failure or ventricular dysfunction—vasodilation can reduce perfusion
- No beta-blocker withdrawal protection: Clevidipine does not prevent rebound from abrupt beta-blocker cessation—continue or taper metoprolol and similar agents per prescriber plan
- Rebound hypertension: After prolonged infusion without transition, monitor blood pressure for at least 8 hours after discontinuation
- Lipid load: Emulsion contributes 0.2 g/mL lipid—coordinate with nutrition and pharmacy when multiple lipid sources run
Important interactions
| Issue | Effect | Nursing action |
|---|---|---|
| Same-line medications | Incompatibility risk; emulsion integrity | Dedicated line only—do not co-infuse other drugs in the clevidipine line |
| Additive hypotension | Concurrent vasodilators, anesthetics, or diuretics may deepen blood pressure drop | Coordinate rate changes with anesthesia and prescriber; reassess after bolus sedatives |
| Reflex tachycardia | Compensatory HR rise may worsen ischemia in susceptible patients | Report sustained tachycardia with hypotension or chest symptoms |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous infusion only—0.5 mg/mL clevidipine injectable emulsion. Do not dilute. Administer through a dedicated line; the labeling permits certain compatible fluids in the same line when appropriate per pharmacy guidance, but never administer other medications through the clevidipine line.
- Invert vial gently before withdrawal; emulsion should appear homogenous—do not use if discolored or separated
- Discard vial 12 hours after puncture per labeling
- Program pump in mg/hour and verify against mL/hour using 0.5 mg/mL concentration
- Independent double-check for rate changes during upward titration windows
Co-infusing medications or diluting Cleviprex can cause unpredictable blood pressure swings and emulsion instability. Label the line clearly and communicate dedicated-line status at handoff.
Expected therapeutic response
- Measurable blood pressure decline within minutes of a rate increase when titrated per protocol
- Blood pressure stabilizes within the ordered range without symptomatic hypotension
- Heart rate may rise modestly—excessive tachycardia suggests overshoot or hypovolemia
- Oral or alternative antihypertensive therapy available before infusion discontinuation when used beyond brief control
Red flags — Stop and act
Escalate immediately for perfusion failure, neurologic change, or uncontrolled overshoot.
- Systolic blood pressure below prescriber threshold with dizziness, confusion, or cool clammy skin—decrease rate and notify prescriber
- Sustained reflex palpitations or heart rate above ordered maximum with hypotension
- Oliguria, rising lactate, or chest pain suggesting hypoperfusion during aggressive titration
- Approaching 1000 mL/24-hour volume limit without transition plan—pharmacy and prescriber coordination
- Blood pressure rebound above baseline within 8 hours after stop when no oral coverage was started
Adverse effects
| Adverse effect | Frequency (labeling) | Nursing response |
|---|---|---|
| Headache | >2% | Assess blood pressure—may reflect rapid lowering; avoid attributing solely to analgesic need without vitals |
| Nausea / vomiting | >2% | Rule out hypotension and nausea from perfusion change; document timing with rate changes |
| Hypotension / reflex tachycardia | Expected pharmacologic effects if excessive | Decrease infusion rate per label; monitor for ischemic symptoms |
| Myocardial infarction, cardiac arrest, syncope | Rare serious events reported | Activate emergency response for collapse, arrest, or acute ischemia—stop infusion |
On a small screen, swipe or scroll sideways to see the full table.
Common adverse events in labeling also include headache and nausea as distinct monitoring cues when titrating in postoperative patients.
Overdose, toxicity, and antidote
Human overdose experience is not reported in the prescribing information. Expected effects are hypotension and reflex tachycardia.
Management (labeling)
- Discontinue clevidipine infusion immediately
- Support blood pressure with fluids, vasopressors, and positioning per protocol and prescriber orders
- Monitor heart rate and perfusion until stable
Antidote: No specific reversal agent is listed—treatment is supportive.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Cleviprex vs other IV antihypertensive bags—verify drug name, concentration (0.5 mg/mL), and line assignment at pump programming; do not confuse with nicardipine or nitroprusside drips
- Emulsion vs aqueous IV bags—Cleviprex is a white to off-white emulsion; do not substitute look-alike clear solutions
- mg/hour vs mL/hour—independent double-check every titration; 0.5 mg/mL means 2 mL/hour = 1 mg/hour
- Vial beyond 12 hours—discard and obtain new vial; do not extend beyond labeling puncture limit
- Shared-line errors—label dedicated clevidipine line at catheter and pump
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Titration log | Document rate, blood pressure, and heart rate after each change—especially during double-every-90-second phase |
| Overshoot recovery | Decrease rate first; small bolus fluids only per prescriber—avoid reflex upward titration after hypotension |
| Alternative agents | When clevidipine is unavailable or contraindicated, teams may choose labetalol or other IV antihypertensives per formulary—never interchange without new orders |
| Stop checklist | Confirm oral antihypertensive ordered and administered (or other plan) before turning off pump |
| Handoff | State current mg/hour, mL infused in 24 hours, lipid sources running, and rebound monitoring plan |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Severe aortic stenosis | Contraindicated—fixed obstruction limits compensatory perfusion during vasodilation |
| Heart failure / low ejection fraction | Negative inotropy warning—monitor for worsening perfusion, pulmonary edema, and renal function |
| Soy or egg allergy | Contraindicated because of emulsion excipients—obtain pharmacy alternative |
| Lipid metabolism disorders / high TPN lipids | Track total lipid exposure; coordinate with nutrition when approaching volume limits |
| Pregnancy | Insufficient human data—use only when benefit clearly outweighs risk per prescriber and maternal-fetal team |
| Lactation | No data in labeling—consult lactation resources and prescriber if breastfeeding patient requires therapy |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure per protocol frequency—more often during active titration (every 1–5 minutes when rates change)
- Heart rate and rhythm for reflex tachycardia or ischemia
- Urine output and perfusion markers when hypotension occurs
- Cumulative infusion volume (mL) and 24-hour lipid load
- Blood pressure for ≥8 hours after discontinuation when prolonged infusion without oral transition
Document
- Start time, indication, initial rate, and prescriber blood pressure targets
- Each titration with paired blood pressure, heart rate, and nurse initials on double-check
- Vial lot, puncture time, and discard at 12 hours
- Transition orders for oral antihypertensives before infusion stop
Patient teaching
- This medication lowers blood pressure quickly through an IV drip—the team will check your blood pressure often and adjust the rate
- Report dizziness, nausea, chest pain, shortness of breath, or pounding heartbeat immediately
- Do not eat or drink soy or egg products if you have allergies listed in your chart—tell nurses about food allergies
- When the drip stops, you may receive oral blood pressure medicines—take them as directed to prevent blood pressure from rising again
- Ask when you can get out of bed; standing too soon after hypotension can cause falls
The Hold Rule
Do not start or continue and contact the prescriber/pharmacist when:
- Soy, egg, or lipid emulsion allergy; defective lipid metabolism; or severe aortic stenosis
- Symptomatic hypotension or prescriber-defined blood pressure below goal—decrease or hold rate and notify before re-titrating upward
- Excessive reflex tachycardia with chest pain, ischemic ECG changes, or poor perfusion
- Vial beyond 12-hour puncture limit or emulsion appears separated or discolored
- Approaching 1000 mL/24-hour volume without transition plan or lipid load review
- No oral or alternative antihypertensive plan when discontinuation is imminent—prevent rebound
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Clevidipine is an ultrashort-acting IV vasodilator—nursing safety centers on pump discipline, perfusion surveillance, lipid accounting, and deliberate transition to oral therapy.
1. Check-before-you-give protocol
- Right patient, drug, concentration (0.5 mg/mL), rate in mg/hour, dedicated line, and allergy screen
- Blood pressure target and maximum rate/volume limits written and verified
- Vial inverted, within 12-hour puncture window, and line labeled “Clevidipine only”
- Transition medication orders active or scheduled before planned stop
2. High-alert and safety badge
Not a standalone high-alert drug on all lists — treat continuous IV titration with high-alert safeguardsISMP emphasizes independent double-checks, pump programming verification, and structured monitoring for IV vasoactive titrations even when clevidipine is not on a facility’s standalone high-alert list.
3. Clinical workflow: hold and question rules
- If blood pressure drops below goal within minutes of a rate increase, decrease the rate first—question any new order to increase without reassessment interval
- If infusion approaches 24-hour mL cap, notify prescriber and pharmacy before exceeding lipid limits
- If oral antihypertensives are held without clevidipine transition plan, clarify before discontinuing infusion
4. Critical teach-back questions
- “What symptoms should you report while this blood pressure drip is running?” (Dizziness, chest pain, pounding heartbeat, severe headache.)
- “What happens to your blood pressure medicine when the IV drip stops?” (Patient should name oral medicines and importance of taking them to avoid rebound.)
5. Care coordination
Pharmacist: Line compatibility, lipid load with TPN, vial beyond-use timing, and transition drug selection
Prescriber / anesthesia / ICU team: Blood pressure targets, maximum rates, oral agent orders before stop, and rebound monitoring duration
🧠 Quick mental checklist
- Allergy screen negative for soy, egg, and lipid disorders—and no severe aortic stenosis?
- Dedicated line labeled, 0.5 mg/mL verified, and vial within 12-hour puncture limit?
- Last titration paired with blood pressure and heart rate—any overshoot needing rate decrease?
- mL infused in 24 hours and lipid sources tracked before approaching 1000 mL cap?
- Oral antihypertensive transition in place before I stop this infusion?
Clevidipine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for clevidipine infusion safety using a tabbed case (MAR, labs, vitals, and nursing notes), plus priority action, select-all-that-apply cues, trend interpretation, matrix urgency, and documentation cloze items tied to hypotension, titration, and rebound risk.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Clevidipine (Cleviprex) 0.5 mg/mL IV infusion — current rate 8 mg/hour via dedicated peripheral line (started 2 hours ago at 2 mg/hour)
- Metoprolol 25 mg PO daily (held this morning per anesthesia)
- Orders: maintain SBP 140–160 mmHg post–cardiac surgery; notify if SBP <110 or HR >120
- Basic metabolic panel: sodium 138, potassium 4.2, creatinine 1.1 mg/dL (baseline 1.0)
- Triglycerides 210 mg/dL (patient also on lipid-containing TPN)
- Clevidipine volume infused past 24 h: 620 mL emulsion
- 1030: BP 102/58 mmHg, HR 118 bpm, MAP 73, SpO2 96% on 2 L NC
- 1015: BP 128/72 mmHg, HR 92 bpm after rate increased from 6 to 8 mg/hour
- 1000: BP 168/88 mmHg, HR 88 bpm before last titration
- Urine output 35 mL/hr past 2 hours (down from 60 mL/hr)
- Patient reports dizziness and “heart pounding” since rate change
- No egg or soy allergy documented at admission — allergy band verified
- Plan discussed to start oral antihypertensive “later today”; none charted yet
- Nurse note: pump programmed in mg/hour; line labeled Cleviprex only
Answer key & rationale
Frequently asked questions
What should nurses check before starting clevidipine?
Confirm no soy or egg allergy, no contraindicated lipid metabolism disorder or severe aortic valve stenosis, verify a dedicated IV line and pump programming at 0.5 mg/mL, and establish blood pressure goals with a transition plan to oral therapy.
When should the clevidipine infusion rate be decreased or held?
When systemic hypotension or excessive reflex tachycardia occurs, decrease the dose per the label and reassess. Hold and notify the prescriber for symptomatic low blood pressure, neurologic changes, or when approaching 24-hour lipid-volume limits.
Why is rebound hypertension a concern after stopping clevidipine?
Because clevidipine has a very short offset (about 5–15 minutes), blood pressure can rise again if patients are not transitioned to other antihypertensive therapy. Prolonged infusions without transition require monitoring for rebound for at least 8 hours after stopping.
Can clevidipine be given with other IV medications in the same line?
No. The prescribing information states clevidipine should not be administered in the same line as other medications, although it may be administered with specific compatible fluids when appropriate per label and pharmacy guidance.
Is there a specific antidote for clevidipine overdose?
Human overdose experience is not reported. Expected effects are hypotension and reflex tachycardia; discontinue the infusion and provide supportive blood pressure management. No specific reversal agent is listed in the prescribing information.
References
-
DailyMed. CLEVIPREX (clevidipine) injectable emulsion prescribing information (setid: a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330). Revised 04/2021.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330
-
U.S. Food and Drug Administration. Cleviprex (clevidipine) NDA 022156 — product labeling PDF.https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330&type=pdf
-
NICE British National Formulary. Clevidipine monograph (where available in local formularies).https://bnf.nice.org.uk/search?q=clevidipine
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.